Catalyst Wire Dossier Catalyst Wire Dossier

Tumor-reactive autologous tumor-infiltrating lymphocytes (TIL)

tumor-infiltrating lymphocytes
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tumor-reactive autologous tumor-infiltrating lymphocytes (TIL), covering 2021-09-22 to 2021-09-22. Get the full timeline:

Most recent: Clinical Trial Update: A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas [Phase 2]

See pricing